Despite favorable lipid profile changes, CETP inhibitors generally fail to reduce cardiovascular events in large trials.
No support for CETP inhibitor use despite lipid changes; leaves open whether novel agents may yet succeed in targeted populations.
Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.
No takes yet. Share an insight, caveat, or question.
Stephen J. Nicholls (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: